XOMA Royalty (NASDAQ:XOMA) executives used the company’s 2025 financial results call to emphasize a year of portfolio expansion, rising royalty receipts, and what management described as progress toward a business model in which recurring royalties can cover core operating costs. Management highlig

Despite a significant drop in Q4 net sales, BioInvent International AB (FRA:BIX0) focuses on promising clinical advancements and strategic partnerships to bolster future growth.

BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with Merck’s KEYTRUDA improved response rates and maintained a favorable safety profile in patients with recurrent ovarian cancer. This early efficacy signal in a difficult-to-treat cancer adds another potential use case for KEYTRUDA, underscoring the importance of Merck’s immuno-oncology collaborations. Next, we’ll examine how this early ovarian cancer data for the...

BioInvent International (OM:BINV) remains unprofitable, with net losses having expanded at a pace of 27.2% per year over the past five years and no improvement in profit margins during that period. Still, revenue is forecast to grow by 22.6% per year and earnings are expected to accelerate by 57.17% per year. The company is projected to achieve profitability within the next three years, outpacing broader Swedish market metrics. Investors may view this combination of substantial projected...

Despite a dip in quarterly sales, BioInvent International AB (FRA:BIX0) advances its lead programs with promising clinical results and strong financial backing.